Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The investigators will investigate the efficacy of dupilumab in patients with severe
eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal
corticosteroids and have significantly extensive disease involving more than 2 sinuses
bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score >=10 at baseline.